Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
AGA guideline favors biologics for moderate to severe ulcerative colitis
Key clinical point: Biologics are preferred over other agents for induction and maintenance of remission in ulcerative colitis.
Major finding: Biologic agents have lower relative risk than that of Janus kinase inhibitors.
Study details: Guideline developed by AGA Institute’s Clinical Guidelines Committee.
Disclosures: Dr. Feuerstein has no relevant financial relationships to disclose. Committee member Kim Isaacs, MD, disclosed relationships with AbbVie, Takeda, UCB, Janssen, and Hoffmann-La Roche. All other committee members have no relevant disclosures.
Feuerstein JD et al. on behalf of the AGA Institute Clinical Guidelines Committee. Gastroenterology. 2020. doi: 10.1053/j.gastro.2020.01.006.